New hope for tough blood cancers: adding a targeted drug to chemo
NCT ID NCT03289910
Summary
This study is testing whether adding a drug called veliparib to a standard two-drug chemotherapy regimen works better for treating advanced blood cancers. It involves 25 adults with specific types of leukemia and related disorders that have progressed or are hard to treat. Participants are randomly assigned to receive either the standard chemo or the standard chemo plus veliparib to see which approach is more effective and safer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California, 92663, United States
Conditions
Explore the condition pages connected to this study.